Abstract

Although complete remission rates in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have improved over the last 2 decades, it is still inferior to that of the pediatric population, and once in remission, the risk of relapse is still high. Furthermore, although pediatric-inspired chemotherapy regimens have improved long-term outcomes for adolescents and young adults, these intensive chemotherapy regimens are not well tolerated in older patients and are associated with higher morbidity and mortality. Immunotherapeutic agents offer a potential opportunity to improve response and decrease relapse without increasing toxicity. The incorporation of rituximab (anti-CD20 monoclonal antibody) into chemotherapy regimens has been shown to improve outcomes. The treatment of BCP-ALL in adults has been transformed with the approval of inotuzumab ozogamicin (anti-CD22 antibody-drug conjugate), blinatumomab (CD3/CD19 bispecific antibody construct), and chimeric antigen receptor T cells for relapsed or refractory disease and of blinatumomab for measurable residual disease (MRD)–positive remission. More recently, studies of inotuzumab and blinatumomab have shown promising results when used up front either with or without multiagent chemotherapy. Blinatumomab has also been shown in a randomized trial to provide a survival benefit in patients with MRD-negative first remission when added to chemotherapy, which recently led to its additional US Food and Drug Administration approval for use in consolidation. In this review, we highlight the evolution of chemoimmunotherapy-based treatment approaches in the management of treatment-naïve BCP-ALL.

1.
Maury
S
,
Chevret
S
,
Thomas
X
, et al
.
Rituximab in B-lineage adult acute lymphoblastic leukemia
.
N Engl J Med
.
2016
;
375
(
11
):
1044
-
1053
.
2.
Jabbour
E
,
Short
NJ
,
Jain
N
, et al
.
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial
.
Lancet Haematol
.
2023
;
10
(
1
):
e24
-
e34
.
3.
Kantarjian
H
,
Ravandi
F
,
Short
NJ
, et al
.
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
.
Lancet Oncol
.
2018
;
19
(
2
):
240
-
248
.
4.
Kantarjian
H
,
Stein
A
,
Gökbuget
N
, et al
.
Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
.
N Engl J Med
.
2017
;
376
(
9
):
836
-
847
.
5.
Badar
T
,
Shah
NN
.
Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia
.
Curr Treat Options Oncol
.
2020
;
21
(
2
):
16
.
6.
Shah
BD
,
Bishop
MR
,
Oluwole
OO
, et al
.
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
.
Blood
.
2021
;
138
(
1
):
11
-
22
.
7.
Park
JH
,
Rivière
I
,
Gonen
M
, et al
.
Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia
.
N Engl J Med
.
2018
;
378
(
5
):
449
-
459
.
8.
Kantarjian
HM
,
DeAngelo
DJ
,
Stelljes
M
, et al
.
Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia
.
N Engl J Med
.
2016
;
375
(
8
):
740
-
753
.
9.
Maude
SL
,
Laetsch
TW
,
Buechner
J
, et al
.
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
.
N Engl J Med
.
2018
;
378
(
5
):
439
-
448
.
10.
Shah
BD
,
Ghobadi
A
,
Oluwole
OO
, et al
.
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
.
Lancet
.
2021
;
398
(
10299
):
491
-
502
.
11.
Gökbuget
N
,
Dombret
H
,
Bonifacio
M
, et al
.
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
.
Blood
.
2018
;
131
(
14
):
1522
-
1531
.
12.
Jabbour
E
,
Short
NJ
,
Jain
N
, et al
.
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial
.
Lancet Haematol
.
2022
;
9
(
12
):
e878
-
e885
.
13.
Jabbour
E
,
Short
NJ
,
Senapati
J
, et al
.
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
.
Lancet Haematol
.
2023
;
10
(
6
):
e433
-
e444
.
14.
Chiaretti
S
,
Della Starza
I
,
Santoro
A
, et al
.
Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult Ph- B-lineage acute lymphoblastic leukemia. Final results of the phase II Gimema LAL2317 Trial [abstract]
.
Blood
.
2023
;
142
(
suppl 1
):
826
.
15.
Wieduwilt
MJ
,
Yin
J
,
Kour
O
, et al
.
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703
.
J Clin Oncol
.
2023
;
41
(
suppl 16
):
7006
.
16.
Chevallier
P
,
Leguay
T
,
KIM
R
, et al
.
Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL): results of the EWALL-INO Study [abstract]
.
Blood
.
2022
;
140
(
suppl 1
):
6114
-
6116
.
17.
Litzow
MR
,
Sun
Z
,
Mattison
RJ
, et al
.
Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults
.
N Engl J Med
.
2024
;
391
(
4
):
320
-
333
.
18.
Thomas
DA
,
O'Brien
S
,
Jorgensen
JL
, et al
.
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
.
Blood, The Journal of the American Society of Hematology
.
2009
;
113
(
25
):
6330
-
6337
.
19.
Hoelzer
D
,
Gökbuget
N
.
Chemoimmunotherapy in acute lymphoblastic leukemia
.
Blood Rev
.
2012
;
26
(
1
):
25
-
32
.
20.
Maury
S
,
Huguet
F
,
Leguay
T
, et al
.
Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
.
Haematologica
.
2010
;
95
(
2
):
324
-
328
.
21.
Thomas
DA
,
O'Brien
S
,
Faderl
S
, et al
.
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
.
J Clin Oncol
.
2010
;
28
(
24
):
3880
-
3889
.
22.
Dworzak
MN
,
Schumich
A
,
Printz
D
, et al
.
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy
.
Blood
.
2008
;
112
(
10
):
3982
-
3988
.
23.
Marks
DI
,
Kirkwood
AA
,
Rowntree
CJ
, et al
.
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial
.
Lancet Haematol
.
2022
;
9
(
4
):
e262
-
e275
.
24.
Ram
R
,
Ben-Bassat
I
,
Shpilberg
O
,
Polliack
A
,
Raanani
P
.
The late adverse events of rituximab therapy--rare but there
.
Leuk Lymphoma
.
2009
;
50
(
7
):
1083
-
1095
.
25.
Carson
KR
,
Evens
AM
,
Richey
EA
, et al
.
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
.
Blood
.
2009
;
113
(
20
):
4834
-
4840
.
26.
Szatrowski
TP
,
Dodge
RK
,
Reynolds
C
, et al
.
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311
.
Cancer
.
2003
;
97
(
6
):
1471
-
1480
.
27.
Seibel
NL
,
Krailo
M
,
O'Neill
K
,
Franklin
J
,
Uckun
F
,
Reaman
GH
.
Phase I study of B43-PAP immunotoxin in combination with standard 4-drug induction for patients with CD 19+ acute lymphoblastic leukemia (ALL) in relapse, a Children's Cancer Group Study
.
Pediatr Res
.
1999
;
45
(
5
):
775
.
28.
Dinndorf
P
,
Krailo
M
,
Liu-Mares
W
,
Frierdich
S
,
Sondel
P
,
Reaman
G
.
Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma
.
J Immunother
.
2001
;
24
(
6
):
511
-
516
.
29.
Badar
T
,
Szabo
A
,
Advani
A
, et al
.
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab
.
Blood Adv
.
2020
;
4
(
10
):
2308
-
2316
.
30.
Topp
MS
,
Gökbuget
N
,
Zugmaier
G
, et al
.
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
.
Blood
.
2012
;
120
(
26
):
5185
-
5187
.
31.
Topp
MS
,
Kufer
P
,
Gökbuget
N
, et al
.
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
.
J Clin Oncol
.
2011
;
29
(
18
):
2493
-
2498
.
32.
Topp
MS
,
Gökbuget
N
,
Stein
AS
, et al
.
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
.
Lancet Oncol
.
2015
;
16
(
1
):
57
-
66
.
33.
Topp
MS
,
Gökbuget
N
,
Zugmaier
G
, et al
.
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
.
J Clin Oncol
.
2014
;
32
(
36
):
4134
-
4140
.
34.
Cabannes-Hamy
A
,
Brissot
E
,
Leguay
T
, et al
.
High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL
.
Haematologica
.
2022
;
107
(
9
):
2072
-
2080
.
35.
Queudeville
M
,
Stein
AS
,
Locatelli
F
, et al
.
Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
.
Cancer
.
2023
;
129
(
9
):
1384
-
1393
.
36.
Jabbour
E
,
Zugmaier
G
,
Agrawal
V
, et al
.
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
.
Am J Hematol
.
2024
;
99
(
4
):
586
-
595
.
37.
Thomas
DA
,
Faderl
S
,
O'Brien
S
, et al
.
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
.
Cancer
.
2006
;
106
(
7
):
1569
-
1580
.
38.
Jabbour
E
,
Richard-Carpentier
G
,
Sasaki
Y
, et al
.
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
.
Lancet Haematol
.
2020
;
7
(
7
):
e523
-
e533
.
39.
Stelljes
M
,
Raffel
S
,
Alakel
N
, et al
.
Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome–negative B-precursor ALL
.
J Clin Oncol
.
2024
;
42
(
3
):
273
-
282
.
40.
Litzow
MR
,
Sun
Z
,
Paietta
E
, et al
.
Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial [abstract]
.
Blood
.
2022
;
140
(
suppl 2
):
LBA-1
.
41.
Foà
R
,
Bassan
R
,
Elia
L
, et al
.
Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL
.
J Clin Oncol
.
2024
;
42
(
8
):
881
-
885
.
42.
Advani
AS
,
Moseley
A
,
O’Dwyer
KM
, et al
.
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia
.
Blood Adv
.
2023
;
7
(
7
):
1279
-
1285
.
43.
Schrappe
M
,
Locatelli
F
,
Valsecchi
MG
, et al
.
Pediatric patients with high-risk B-cell ALL in first complete remission may benefit from less toxic immunotherapy with blinatumomab - results from randomized controlled phase 3 trial AIEOP-BFM ALL 2017 [abstract]
.
Blood
.
2023
;
142
(
suppl 1
):
825
.
44.
Advani
AS
,
Moseley
A
,
O'Dwyer
KM
, et al
.
SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed philadelphia chromosome–negative B-cell acute lymphoblastic leukemia
.
J Clin Oncol
.
2022
;
40
(
14
):
1574
-
1582
.
45.
DeAngelo
DJ
,
Stock
W
,
Stein
AS
, et al
.
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
.
Blood Adv
.
2017
;
1
(
15
):
1167
-
1180
.
46.
Kantarjian
H
,
Thomas
D
,
Jorgensen
J
, et al
.
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
.
Lancet Oncol
.
2012
;
13
(
4
):
403
-
411
.
47.
Geyer
MB
,
Hsu
M
,
Devlin
SM
,
Tallman
MS
,
Douer
D
,
Park
JH
.
Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis
.
Blood
.
2017
;
129
(
13
):
1878
-
1881
.
48.
DeAngelo
DJ
,
Advani
AS
,
Marks
DI
, et al
.
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
.
Blood Cancer J
.
2020
;
10
(
8
):
81
.
49.
Cahill
K
,
Alban
J
,
Mortel
M
, et al
.
Low incidence of hepatic veno-occlusive disease (VOD) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin (INO) followed by allogeneic stem cell transplantation (allo-SCT)
.
J Clin Oncol
.
2021
;
39
(
suppl 15
):
e19024
.
50.
Zhao
Y
,
Short
NJ
,
Kantarjian
HM
, et al
.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL
.
Blood
.
2024
;
144
(
1
):
61
-
73
.
51.
Stock
W
,
Luger
SM
,
Advani
AS
, et al
.
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
.
Blood
.
2019
;
133
(
14
):
1548
-
1559
.
52.
McNeer
JL
,
O'Brien
MM
,
Rheingold
SR
, et al
.
A phase 3 randomized trial of inotuzumab ozogamicin for newly diagnosed high-risk B-ALL: safety phase results from Children's Oncology Group Protocol AALL1732 [abstract]
.
Blood
.
2021
;
138
(
suppl 1
):
3398
.
53.
Marconi
G
,
Piciocchi
A
,
Chiaretti
S
, et al
.
GIMEMA ALL2418: interim analysis of a phase Iia Study of feasibility and effectiveness of inotuzumab ozogamicin in adult patients with B-cell acute lymphoblastic leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation [abstract]
.
Blood
.
2022
;
140
(
suppl 1
):
6119
-
6121
.
54.
Jabbour
E
,
Haddad
FG
,
Short
NJ
, et al
.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission
.
Blood
.
2024
;
143
(
5
):
417
-
421
.
55.
Jabbour
E
,
Haddad
FG
,
Short
NJ
,
Kantarjian
H
.
Treatment of adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—from intensive chemotherapy combinations to chemotherapy-free regimens: a review
.
JAMA Oncol
.
2022
;
8
(
9
):
1340
-
1348
.
56.
Badar
T
,
Alkhateeb
H
,
Aljurf
M
,
Kharfan-Dabaja
MA
.
Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era
.
Curr Res Transl Med
.
2023
;
71
(
2
):
103392
.
57.
Foà
R
,
Bassan
R
,
Vitale
A
, et al
.
Dasatinib–blinatumomab for Ph-positive acute lymphoblastic leukemia in adults
.
N Engl J Med
.
2020
;
383
(
17
):
1613
-
1623
.
58.
Maude
SL
,
Laetsch
TW
,
Buechner
J
, et al
.
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
.
N Engl J Med
.
2018
;
378
(
5
):
439
-
448
.
59.
Pillai
V
,
Muralidharan
K
,
Meng
W
, et al
.
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
.
Blood Adv
.
2019
;
3
(
22
):
3539
-
3549
.
60.
Schultz
LM
,
Baggott
C
,
Prabhu
S
, et al
.
Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report
.
J Clin Oncol
.
2022
;
40
(
9
):
945
-
955
.
61.
Locke
FL
,
Rossi
JM
,
Neelapu
SS
, et al
.
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
.
Blood Adv
.
2020
;
4
(
19
):
4898
-
4911
.
62.
Jacobs
MT
,
Jain
MD
,
Gao
F
, et al
.
Severity of cytokine release syndrome influences outcome after axicabtagene ciloleucel for large B cell lymphoma: results from the US Lymphoma CAR-T Consortium
.
Clin Lymphoma Myeloma Leuk
.
2022
;
22
(
10
):
753
-
759
.
63.
Jain
MD
,
Smith
M
,
Shah
NN
.
How I treat refractory CRS and ICANS after CAR T-cell therapy
.
Blood
.
2023
;
141
(
20
):
2430
-
2442
.
64.
Niu
J
,
Qiu
H
,
Xiang
F
, et al
.
CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
.
Blood Cancer J
.
2023
;
13
(
1
):
44
.
65.
Lu
W
,
Wei
Y
,
Cao
Y
, et al
.
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
.
Cancer Immunol Immunother
.
2021
;
70
(
12
):
3501
-
3511
.
You do not currently have access to this content.
Sign in via your Institution